Structure–activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors
Graphical abstract
.
Section snippets
Acknowledgments
The authors thank Partners Healthcare for financial support. This work was also supported in part by NIH Grants HL079943 (P.B.Y.), HL074352 (K.D.B.), and HL079267 (R.T.P.), the Harvard NeuroDiscovery Center (G.D.C., X.X. and J.K.L.), a Pulmonary Hypertension Association Mentored Clinical Scientist Award (P.B.Y.) and a grant from the GlaxoSmithKline Research & Education Foundation for Cardiovascular Disease (P.B.Y.). The pharmacokinetic study was performed by Absorption Systems (Exton, PA) and
References and notes (26)
- et al.
Trends Cardiovasc. Med.
(2007)et al.J Biol. Chem.
(2005) - et al.
Blood
(2007) - et al.
Histol. Histopathol.
(2007) - et al.
Clin. Cancer Res.
(2003) - et al.
J. Bone Miner Res.
(2008)et al.Nat. Genet.
(2006) - et al.
Synlett
(2005) - et al.
J. Org. Chem.
(2003) - et al.
J. Chem. Soc., Perkin Trans. 1
(1975) - et al.
Bioorg. Med. Chem. Lett.
(2004)et al.J. Med. Chem.
(2004)
Growth Factors
(2004)
et al.FEBS Lett.
(2003)
et al.Cell Signal
(2004)
Nat. Chem. Biol.
(2008)
et al.J. Clin. Invest.
(2007)
et al.N. Engl. J. Med.
(2005)
Curr. Opin. Pharmacol.
(2007)
Cited by (291)
Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva
2022, Bioorganic and Medicinal Chemistry LettersInhibition of ALK2 with bicyclic pyridyllactams
2022, Bioorganic and Medicinal Chemistry LettersThe Molecular Circadian Clock Is a Target of Anti-cancer Translation Inhibitors
2024, Journal of Biological RhythmsOxidative phosphorylation is a pivotal therapeutic target of fibrodysplasia ossificans progressiva
2024, Life Science Alliance
Copyright © 2008 Elsevier Ltd. All rights reserved.